Medicines Company (MDCO) Share Price

Looks like Denner will walk away with $431MM from his MDCO position.

If anyone sees Denner/Sarissa make a new significant investment, please post it here. I want to buy into that company.

http://archive.fast-edgar.com//20191219/ANAZE22C8Z22T2ZA22ZE22ZZPK3PZ2X2ZLB6/

$MDCO short squeeze The Medicines Company Nasdaq Mdco Short Squeeze

News: $MDCO Merger Investigation Alert: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - MDCO, AMTD, TIF

NEW YORK, NY / ACCESSWIRE / November 25, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: The Medicines Company (NASDAQ:MDCO) The investigation concerns whether The Medicines Company and its board of directors violated the fe...

Got this from MDCO - Merger Investigation Alert: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - MDCO, AMTD, TIF

News: $MDCO A 45% Premium: Here's Why The Medicines Company Is Worth More to Novartis Than It Was to You

It turns out the rumors were true. Novartis (NYSE: NVS) is buying The Medicines Company (NASDAQ: MDCO) for $85 per share. That's a 45% premium above the closing price prior to the acquisition rumor being published. Investors kicking themselves for not seeing the higher potential valu...

Find out more MDCO - A 45% Premium: Here's Why The Medicines Company Is Worth More to Novartis Than It Was to You

News: $MDCO ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of The Medicines Company

NEW YORK , Nov. 25, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by The Medicines Company (NASDAQ: MDCO) and its board of directors concerning the proposed acquisition of the company by Novartis AG ( NYSE : NVS). Stockholders will receive ...

Got this from MDCO - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of The Medicines Company

News: $MDCO THE MEDICINES COMPANY ALERT: Bragar Eagel & Squire, P.C. Investigates the Proposed Sale of MDCO and Encourages Investors to Contact the Firm

NEW YORK , Nov. 25, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, has launched an investigation into whether the board members of The Medicines Company (NASDAQ: MDCO) breached their fiduciary duties or violated the federal securities l...

Got this from MDCO - THE MEDICINES COMPANY ALERT: Bragar Eagel & Squire, P.C. Investigates the Proposed Sale of MDCO and Encourages Investors to Contact the Firm

News: $MDCO Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders - MDCO, AMTD, TIF, BREW

NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: The Medicines Company (NASDAQ: MDCO) The investigation concerns whether The Medicines Company and its board of directors violated the ...

Got this from MDCO - Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders - MDCO, AMTD, TIF, BREW

News: $MDCO Is Alnylam Stock a Good Buy Now?

It took two solid decades for  Alnylam   (NASDAQ: ALNY)  to carry its first new drug candidate across the finish line, but investors didn't need to wait long for the next one. The FDA approved the company's second drug just 16 months later, and the pace will probably accelerate.&#...

Got this from MDCO - Is Alnylam Stock a Good Buy Now?

Ambulance chasing at its finest

News: $MDCO (MDCO) Alert: Johnson Fistel Investigates Proposed Sale of The Medicines Company; Is $85 a Fair Price?

SAN DIEGO , Nov. 25, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of The Medicines Company (NASDAQ: MDCO) breached their fiduciary duties in connection with the proposed sale of the Company to Novart...

Read the whole news MDCO - (MDCO) Alert: Johnson Fistel Investigates Proposed Sale of The Medicines Company; Is $85 a Fair Price?

Boom!

News: $MDCO Here's Why The Medicines Company Jumped Higher Again Today

Shares of The Medicines Company (NASDAQ: MDCO) are up 18.6% at 12:19 p.m. EST after Bloomberg reported that the drugmaker had gotten interest from potential acquirers, including Novartis (NYSE: NVS) . A potential suitor would be after The Medicines Company's cholesterol-lowering drug inc...

Read the whole news MDCO - Here's Why The Medicines Company Jumped Higher Again Today

News: $MDCO Here's Why The Medicines Company Moved Higher Today

Shares of The Medicines Company (NASDAQ: MDCO)  closed the trading day up 12.8% following the presentation of two phase 3 clinical trials testing cholesterol-lowering drug inclisiran at the American Heart Association's Scientific Sessions in Philadelphia. Shares of Alnylam Pharmaceutica...

Find out more MDCO - Here's Why The Medicines Company Moved Higher Today

News: $MDCO The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing

- Inclisiran achieved 50% LDL-C lowering with time-adjusted reductions of 45% sustained over 18 months of treatment in patients with heterozygous familial hypercholesterolemia (HeFH) - ORION-9 further demonstrated inclisiran’s excellent safety profile, including no treatment-relate...

In case you are interested MDCO - The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing

News: $MDCO The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD) - ORION-10 study affirmed inclisiran’s excellent safety profile, including no treatment-related liver ...

Read the whole news MDCO - The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

Whew, what's up today? Ppl concerned about the cash bleed?

News: $MDCO The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients

­ ORION-10 study met all primary and secondary endpoints, with durable and potent efficacy and excellent safety of inclisiran that were at least as favorable as observed in ORION-11 ­ ORION-10 completion marks successful conclusion of pivotal Phase 3 LDL-C lowering studies of in...

In case you are interested MDCO - The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients

News: $MDCO The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients

­ ORION-9 study met all primary and secondary efficacy endpoints ­ Inclisiran demonstrated durable and potent efficacy and excellent safety in a patient population where cardiovascular disease is most severe ­ Detailed data from ORION-9 will be presented in a late-breaki...

Find out more MDCO - The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients

News: $MDCO MDCO Stock Hits 2-Year High After Robust Clinical Data

When pharmaceutical companies manage to get highly positive results from clinical trials of one of their more important products, then it almost always has a positive impact on the stock price, and that is what happened with MDCO stock. Solid Boost The Medicines Company (NASDAQ:MDCO) an...

Find out more MDCO - MDCO Stock Hits 2-Year High After Robust Clinical Data

News: $MDCO The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran

­ ORION-11 study met all primary and secondary efficacy endpoints with efficacy consistent with Phase 1 and 2 studies ­ Safety profile of inclisiran was at least as favorable as in ORION-1 Phase 2 and ORION-3 open-label extension studies ­ Detailed data will be presented...

In case you are interested The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran

News: $MDCO The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress

Inclisiran administration led to consistent LDL-C reductions, with no dose adjustment required regardless of renal function, in a combined analysis of ORION-1 and ORION-7 studies Late-breaking abstract presentation of ORION-2 study showed that inclisiran significantly lowered LDL-C wit...

Find out more https://marketwirenews.com/news-releases/the-medicines-company-presents-clinical-data-analyses-for-inclisiran-at-87th-european-atherosclerosis-society-congress-8251204.html

Anyone active on this board?

https://www.fairfieldcurrent.com/2018/10/05/the-medicines-mdco-and-innovus-pharmaceuticals-innv-head-to-head-comparison.html

It’s gonna happen I tell ya

This co is getting bought out soon

Not sure about that. It looks more like a bet-the-company decision on Inclisiran.

Looks like preparing to sell the company.

MDCO to divest/layoff ~80% of workforce: #msg-135682595.

scam and fraud as an investor you entrust you money so they can grow their business and you can profit from their discussions. I was in TARGA# which sold out its investors and sold themselves to MDCOWS\. Too many lawsuits they get paid no matter what.

yup, no one knows about it

APPROVED HOT HOT HOT FDA NDA

Under radar still AH get some

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm

Partner Fund Management, L.P. has filed a new 13G, reporting 5.3% ownership in $MDCO - https://fintel.io/so/us/mdco

MDCO bullish 54.07

bull flag









normal chart




log chart

Yea... cash flow analyses imply Medicines Co $MDCO is 18% overvalued b4 earnings Wednesday:

Fair Value Source

MDCO - Fair value is around $5-7...

But when has the market made any sense?

This is a buyout target. Look at the top big Pharma companies that need to line their cardiovascular pipeline.

Clive is a crafty chap, I will give him that...

This company will be acquired sooner than later.

This could be a buying bubble based upon Amgen news...

LOL,..do you even keep up with the latest developments of this company ?

are you even a shareholder oh bringer of negative (fake) news?

really. "UNPROFITABLE SCAM" based on what ? your opinion. you post a few words of discouragement and the MDCO forum is obliged to believe you ? LOL.


i guess the MDCO principals/insiders are not in the same loop of info as your privy in that they parallel VRX,...

hmmm,..explain this ,....in Dec 16 insiders bought over 640,000 shares at average market price of $34.05.

for this $30 stock that totals about $12,870,000 in cash,...

so they, the principals, have some skin in the game.

my prediction,..

their products will hit big !!!! and in case you don't follow the company results and it's milestones

,...The company is developing a compound called Inclisiran that looks really promising. This is one of the new types of cholesterol-lowering drugs and has significant potential. Insiders certainly believe they have a valuable asset.


so why would company insiders buy millions of dollars in their own company stock IF there is nothing to be had as you suggest ? why ?

and they bought in Dec'16 when the price was $33,..now the price is $45,...ya think they had an idea that things will start moving in a positive direction ?

yea,...i guess they need to get in iHub MDCO forum to get the real deal from you,....LOL

Medicines Company has thrown itself into R&D since it faced a patent cliff some years ago. Results have been good, with approval for its skin-infection treatment Orbactiv in 2014, its blood-thinner Kengreal and fentanyl patch Ionsys in 2015, and positive topline results from a phase III study its urinary tract infection drug carbavance which was announced in June 2016. Carbavance will have an NDA submitted early 2017. This is a lot of good news, and if inclisiran can also show success, then MDCO will be looking at many years of strong revenue growth from its products and pipeline.

Thanks Dew. Quick 50 was a nice day. I'll keep trading thru news.

This isn't necessarily a big win for the PCSK9 class—see #msg-128416849. Regards, Dew

$3.2 BILLION UNPROFITABLE SCAM + $700 MILLION DEBT = STRONG SELLLLLLLL THIS BRUTALY PUMPED PONZI SCHEME BUBBLE . Another Scam like Valeant (VRX) here ,fair value is around $5-7 AT MAX .

MDCO Up 5.45 after hours on AMGEN coat tails from the REPATHA drug study. MDCO's drug is more effective and safer and will cost less.

Thanks. Do more due.

I'm not sure. MDCO is a totally remade company in the past couple of years. I followed the Angiomax story pretty closely (partly because I was long EGRX), but I know less about MDCO's new portfolio.

We if you were on it its worth being here. What's your thoughts on this company Dew.

This has never been an active board.

Why did the posting stop?

MDCO drops ApoA-1 Milano program: #msg-126382539.

MDCO +6%/PM on ORION-1 data: #msg-125863956.

MDCO -11% on ALNY fallout. MDCO’s PCSK9 drug was licensed from ALNY (http://finance.yahoo.com/news/medicines-company-provides-progress-ongoing-203500482.html ).

MDCO - Nothing but speculation supporting this company now.

MDCO -10%/AH on Apo-A-1-Milano interim analysis: #msg-124870392.